Casey, Dana L. http://orcid.org/0000-0001-6851-7653
Pitter, Kenneth L.
Wexler, Leonard H.
Slotkin, Emily K.
Gupta, Gaorav P. http://orcid.org/0000-0001-9177-552X
Wolden, Suzanne L.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748, P30CA008748, P30CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 2 March 2021
Revised: 28 April 2021
Accepted: 10 May 2021
First Online: 20 May 2021
Ethics approval and consent to participate
: Consent for genomic testing was obtained under the prospective protocol (#12–245) through the Memorial Sloan Kettering Cancer Center Institutional Review Board. Consent to participate in this retrospective analysis was waived by the Memorial Sloan Kettering Cancer Center Institutional Review Board approved protocol (#16–1125). This study was performed in accordance with the Declaration of Helsinki.
: No personal data or identifying information are being submitted.
: Data are relevant to MSKCC patients and not publicly available. We will make de-identified data available upon request after institutional approval.
: D.L.C., K.L.P., L.H.W., E.K.S., G.P.G. and S.L.W. declare no competing interests. L.H.W. held a consultant position at EUSA Pharma in 2019, not relevant to this work.
: National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30CA008748).